Dr. Moore's clinical and laboratory research focuses on the development and testing of new cancer therapies, particularly in the areas of prostate and pancreatic cancers.
He is director of the Bras Family Drug Development Program at Ontario Cancer Institute/Princess Margaret Hospital. This program was selected by the NIH as one of seven north American sites to perform new drug development of novel anti-cancer agents. This has lead to a major expansion of both the laboratory and clinical components of the drug development program.
Areas of focus for new drug development are signal transduction inhibitors, modulation of gene expression and angiogenesis.
- Ho Chair in Prostate Cancer Research, Princess Margaret Cancer Centre
- Chair of the National Cancer Institute of Canada GI cancer disease site
- Professor, Department of Medicine and Pharmacology, University of Toronto